Rivulet Media Inc (fka RIVU)

[InvestorStemCell]

eligible for Orphan Drug Status which makes HemaXellerate I™ able to get full FDA approval in as little as 60 days to bypass the lengthy Phase I, II, III, IV FDA Approval Processes because of being eligible for Orphan Drug Status

YOU SAID---



That is inaccurate. Where did you see this on the web?

Orphan Drug Regulation was brought forth in 83 to help give reason for researchers to look into small populations of illness and corporation to fund such investigations It offers tax incentives, longer protection via patents and market protection. but nowhere anywhere does Orphan Drug Status permit the side stepping of a clinical trials .